These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12234333)

  • 1. Progressive renal and cardiovascular disease: optimal treatment strategies.
    Weir MR
    Kidney Int; 2002 Oct; 62(4):1482-92. PubMed ID: 12234333
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibition in renal and hypertensive disorders.
    Götz R; Heidbreder E; Heidland A
    Clin Physiol Biochem; 1990; 8 Suppl 1():25-32. PubMed ID: 2257721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Slowing nephropathy progression: focus on proteinuria reduction.
    Bakris GL
    Clin J Am Soc Nephrol; 2008 Jan; 3 Suppl 1(Suppl 1):S3-10. PubMed ID: 18178794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE inhibitors in renal disease.
    Brunner HR
    Kidney Int; 1992 Aug; 42(2):463-79. PubMed ID: 1405331
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapeutic strategy for progressive renal disease].
    Hayashi K; Ozawa Y; Tokuyama H
    Nihon Rinsho; 2001 May; 59(5):955-60. PubMed ID: 11391998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The use of angiotensin-converting enzyme inhibitors in chronic diffuse kidney diseases].
    Kutyrina IM; Tareeva IE; Gerasimenko OI; Rogov VA; Miroshnichenko NG
    Ter Arkh; 1995; 67(5):20-3. PubMed ID: 7638769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. REIN on obesity, proteinuria and CKD.
    Choi ME
    J Am Soc Nephrol; 2011 Jun; 22(6):990-2. PubMed ID: 21617125
    [No Abstract]   [Full Text] [Related]  

  • 8. The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises.
    Schieppati A; Remuzzi G
    Kidney Int; 2003 Dec; 64(6):1947-55. PubMed ID: 14633117
    [No Abstract]   [Full Text] [Related]  

  • 9. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?
    van Essen GG; Apperloo AJ; Rensma PL; Stegeman CA; Sluiter WJ; de Zeeuw D; de Jong PE
    Kidney Int Suppl; 1997 Dec; 63():S58-62. PubMed ID: 9407423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Summaries for patients. Using a type of blood pressure medicine, angiotensin-converting enzyme inhibitors, to prevent worsening of kidney disease unrelated to diabetes.
    ACE Inhibition in Progressive Renal Disease Study Group
    Ann Intern Med; 2001 Jul; 135(2):S-21. PubMed ID: 11463005
    [No Abstract]   [Full Text] [Related]  

  • 11. Introduction: nature of microalbuminuria, proteinuria, and progressive renal disease.
    Mogensen CE
    J Diabetes Complications; 1995; 9(1):2-6. PubMed ID: 7734738
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting the renin-angiotensin system in patients with renal disease.
    Devonald MA; Karet FE
    J R Soc Med; 2002 Aug; 95(8):391-7. PubMed ID: 12151488
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of amlodipine and enalapril alone and in combination on glomerular hemodynamics in a hypertensive patient with unilaterally contracted kidney.
    Passavanti G; Vernaglione L; Mancini A
    Nephron; 1998; 78(3):350-1. PubMed ID: 9546705
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antihypertensive treatment for chronic kidney disease].
    Kumagai H; Hyodo T; Kushiyama T; Higashi K; Yamamoto K
    Nihon Rinsho; 2008 Aug; 66(8):1574-81. PubMed ID: 18700560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How should renin-angiotensin system blockade be applied in chronic kidney disease for optimal renal protection?
    Zhang X; Hou FF
    Chin Med J (Engl); 2007 Feb; 120(3):243-5. PubMed ID: 17355830
    [No Abstract]   [Full Text] [Related]  

  • 18. [Modification of renal hemodynamics and proteinuria in patients with arterial hypertension and kidney diseases].
    Risler T; Erley CM
    Z Kardiol; 1993; 82 Suppl 4():39-44. PubMed ID: 7908476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening and treatment of diabetic renal disease.
    Clement JD; Cottiero RA
    Med Health R I; 1998 Nov; 81(11):348-9. PubMed ID: 15580788
    [No Abstract]   [Full Text] [Related]  

  • 20. Calcium channels blockers and progression of kidney disease.
    Ziakka S; Kaperonis N; Ferentinou E; Karakasis F; Ntatsis G; Kourvelou C; Papagalanis N
    Ren Fail; 2007; 29(8):1003-12. PubMed ID: 18067048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.